★ America V2AuditLine ALPHA

AuditLine › HHS OIG › Centers for Medicare and Medicaid Services

HHS OIG recommendation 19-A-06-081.01

We recommend that CMS seek legislative change to exclude authorized generic drug transactions to secondary manufacturers from the AMP calculation of…

Closed ImplementedThe publisher's status, as reported by HHS Office of Inspector General in the file read .

The recommendation, in the publisher's words

We recommend that CMS seek legislative change to exclude authorized generic drug transactions to secondary manufacturers from the AMP calculation of the brand name drug.
Responsible agency
Centers for Medicare and Medicaid Services
Issued
April 29, 2019
Report
Medicaid Could Save Hundreds of Millions by Excluding Authorized Generic Drug Transactions to Secondary Manufacturers from Brand Name Drugs' Average Manufacturer Price Calculations (A-06-18-04002) · find it at HHS OIG
Kind of report
Audit
Agency response
Concur (as recorded by the publisher)
Closed
June 13, 2023 (publisher's date)
Publisher flags
Legislative
Publisher topics
Prescription Drug

“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.

Dated history

  1. Issued by HHS OIG. (publisher's date)
  2. Closed, with status “Closed Implemented”. (publisher's date)
  3. First recorded by AuditLine. (start of AuditLine's own history for this record)

Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.

Source

Open this report in HHS OIG's tracker This publisher's records (CSV)

Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows, SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.